Next 10 |
2024-06-28 17:32:09 ET More on FibroGen FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript FibroGen stock rall...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
2024-06-06 12:38:52 ET Summary FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the...
2024-06-03 17:38:01 ET More on FibroGen Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug Seeking Alpha’...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumors Plan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (...
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:0...
2024-05-28 06:10:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases ...
2024-05-28 00:08:10 ET Summary FibroGen focuses on developing Pamrevlumab for pancreatic cancer therapy after disappointing trial results for other indications. If successful, Pamrevlumab’s phase 3 trials in pancreatic cancer could be a major value driver. Roxadustat ha...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...